Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1628301

	registered interest
	date	16/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Advanced Therapy Medicinal Products
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of reviewing the way the National Institute for Health and Care Excellence and NHS England evaluate and adopt Advanced Therapy Medicinal Products as technologies with the potential to deliver significant health gains over long periods of time.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	185240
	answer	answer is ministerial correction date of answer 25/05/2023 answer text <p>The National Institute of Health and Care Excellence (NICE) recently carried out a comprehensive review of its methods and processes for health technology evaluation to ensure that they were appropriate to emerging new technologies such as advanced therapeutic medicinal products (ATMPs). NICE published its updated health technology evaluation manual in January 2022 and has introduced a number of changes that ensure that its appraisal processes are suitable for emerging new medicines, including a broader severity modifier and changes to better respond to uncertainty. There are no plans for a further assessment of NICE’s processes for evaluating ATMPs.</p><p> </p><p>NICE’s methods and processes have been proven to be suitable for ATMPs where companies are willing to price their products in a way that represents value to the taxpayer. NICE has recommended 80% of the ATMPs it has evaluated for use by the National Health Service and they are now available for the treatment of NHS patients, including through the Cancer Drugs Fund and managed access agreements negotiated between the NHS and the manufacturer.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/05/2023 12:35:12 answering member 4423 label Biography information for Will Quince
	tabling member	3960 label Biography information for Henry Smith

1039028

	registered interest
	date	10/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asparaginase
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether Erwinase will be available for the treatment for children with acute lymphoblastic leukaemia between January 2019 and March 2019; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	207238
	answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed by Jazz Pharmaceuticals under a global licencing agreement.</p><p> </p><p>Due to increased demand for Erwinase and because PBL are manufacturing at capacity, until increases in capacity are brought into beneficial use there will be occasional stock-outs.</p><p> </p><p>The product is currently in stock in the United Kingdom. The Department has been informed, it is likely there will be a short stock-out in early February 2019 and then a further batch is planned to be released to Jazz Pharmaceuticals, who are responsible for the packaging/distribution and allocation of worldwide product supply, anticipated to reach the UK market by mid-February 2019 which should last until the end of March 2019.</p><p> </p><p>The Department and Public Health England (PHE) are in close contact with, and have been kept informed by the PBL management of short periods of interrupted supply. PBL have and will be implementing a series of initiatives to increase capacity and better supply the market in both the short and long term. PBL are fully aware of the consequences that the unavailability of Erwinase has on patients and are absolutely committed to working with all involved to resolve any issues and be able to supply this critical medicine.</p><p> </p><p>The Department and PHE will continue to monitor the situation closely.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2019 12:18:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1050101

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asparaginase
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 January 2019 to Question 207238 on Asparaginase, what steps Porton Biopharma will take to increase capacity of erwinase and better supply the (a) UK and (b) world market for the remainder of 2019.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	213322
	answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Porton Biopharma Ltd (PBL) are implementing a series of initiatives to increase capacity and supply in both the short and long term. These include the following:</p><p>- Extending operational activities to 24 hours a day, seven days a week to maximise fermentation of the product;</p><p>- Implementing an ongoing capital programme including construction of a new pharmaceutical fermentation facility. The facility was completed in April 2018 and is currently undergoing testing; it has an increased capacity fermentation suite which will enable PBL to manufacture at larger scale and is due to start producing product Q3 2019 for regulatory approval to market;</p><p>- A new filling and freeze-drying building was completed in February 2016. The installation of a new filling line which covers the entire process, including vial washing, filling, stoppering and freeze drying. The new line has been designed with systems which monitor all critical parameters throughout the process to accelerate batch release and will accommodate increased capacity. The beneficial use of this and the fermentation facility will coincide to maximise increased product output; and</p><p>- Sourcing replacement suppliers, including for new stoppers and new vials for the product, ensuring that maximum batch sizes can be achieved with minimal product rejects. This programme is complete.</p><p> </p><p>PBL has made significant investments into increasing product capacity and will continue to release future batches as soon as they become available to Jazz Pharmaceuticals (who are responsible for the packaging/distribution and allocation of worldwide product supply).</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:09:48 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1231662

	registered interest
	date	04/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 June 2020 to Question 58767, what plans he has to centrally collate data on the total number of severe asthma patients (a) in England and (b) within each of the NHS E+I regions.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	85020
	answer	answer is ministerial correction date of answer 22/09/2020 answer text <p>There are no plans for this.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 22/09/2020 14:46:46 answering member 4527 label Biography information for Helen Whately
	tabling member	3960 label Biography information for Henry Smith

1231660

	registered interest
	date	04/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 June 2020 to Question 60724, what steps his Department is taking to ensure at-home treatment of severe asthma patients is available and offered to all patients; and what assessment has been made of the clinical capacity released within respiratory units as a result of such home management.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	85018
	answer	answer is ministerial correction date of answer 05/11/2020 answer text <p>Specialist respiratory services for severe asthma, along with urgent and emergency treatment for other serious complaints, have continued throughout the COVID-19 outbreak. In most cases people with severe asthma have been able to receive their medication at home instead of having to attend hospital through increasing home care support and via access to remote outpatient consultations for new patients.</p><p>Although clinical capacity was re-directed to support care of patients with COVID-19 and this need has reduced, trusts are also required to prepare for potential future waves of COVID-19 and this will affect the clinical capacity required particularly in respiratory units. Regions have oversight of the local plans developed by each trust.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 05/11/2020 12:20:51 answering member 4527 label Biography information for Helen Whately
	tabling member	3960 label Biography information for Henry Smith

1231661

	registered interest
	date	04/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 June 2020 to Question 58769, what assessment he has made of the decline to the number of patients accessing biologics therapies for severe asthma in January to March 2020, and what he has to reverse that decline.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	85019
	answer	answer is ministerial correction date of answer 19/10/2020 answer text <p>The National Institute for Health and Care Excellence COVID-19 rapid guideline on severe asthma provides guidance on starting or continuing on biological treatments, for people with severe asthma during the COVID-19 outbreak. The recommendations were written in collaboration with the NHS England Severe Asthma Collaborative. In writing the guidance, particular attention was paid to streamlining the process of moving patients onto biologic therapies to compensate for any possible barriers that may have occurred as a result of changes to the National Health Service, which were made as part of the necessary response to COVID-19.</p><p>Further work is being undertaken by the collaborative to share best practice on providing care to people with severe asthma to ensure on-going provision of high-quality care and to accelerate the initiation of biologics where required.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 19/10/2020 10:33:39 answering member 4527 label Biography information for Helen Whately
	tabling member	3960 label Biography information for Henry Smith

1541365

	registered interest
	date	09/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bereavement Counselling and Mental Health Services: Veterans
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if his Department will take steps to encourage local authorities to include clear signposting for local veteran-specific support services including (a) mental health services and (b) bereavement support.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	83605
	answer	answer is ministerial correction date of answer 18/11/2022 answer text <p>Local authorities are encouraged to receive updates from the National Health Service which outline initiatives in support of the armed forces community, including information on Op COURAGE. Bereavement support is commissioned locally to meet the need of the local population. NHS England has developed guidance for integrated care boards which requires commissioners to ensure there is sufficient access to bereavement support services.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 18/11/2022 11:56:40 answering member 4492 label Biography information for Maria Caulfield
	tabling member	3960 label Biography information for Henry Smith

1172698

	registered interest
	date	22/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to reduce the number of people with blood cancer visiting their GP three or more times.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	6642
	answer	answer is ministerial correction date of answer 31/01/2020 answer text <p>In 2020, NHS England and NHS Improvement will continue to roll-out Rapid Diagnostic Centres across the country to upgrade and bring together the latest diagnostic equipment and expertise. They will initially focus on diagnosing cancers where patients often present with non-specific symptoms, such as blood cancer, and may go to their general practitioner many times before being sent for appropriate tests.</p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 31/01/2020 11:10:11 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1190700

	registered interest
	date	27/04/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people with blood cancer have received a letter asking them to shield at home for 12 weeks from (a) NHS England and (b) their local clinical care team; and how many of those people have (i) chronic lymphocytic leukaemia and (ii) Myeloproliferative neoplasms.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	40578
	answer	answer is ministerial correction date of answer 18/06/2020 answer text <p>As of May 2020, 164,427 patients had been identified in the category “people with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment” by NHS Digital, and received a letter asking them to shield at home for 12 weeks. The information about how many patients in this category identified locally is not held centrally.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 18/06/2020 17:05:07 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1193071

	registered interest
	date	05/05/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many (a) men (b) women with blood cancer in each age group have (i) contracted covid-19 (ii) received intensive care support and (iii) died with covid-19.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	43625
	answer	answer is ministerial correction date of answer 29/05/2020 answer text <p>This data is not currently held.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 29/05/2020 15:07:52 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith